Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jan;10(1):110-5.
doi: 10.1097/JTO.0000000000000385.

Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials

Primo N Lara Jr  1 , James Moon, Mary W Redman, Thomas J Semrad, Karen Kelly, Jeffrey W Allen, Barbara J Gitlitz, Philip C Mack, David R Gandara
Affiliations
Clinical Trial

Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials

Primo N Lara Jr et al. J Thorac Oncol. 2015 Jan.

Abstract

Background: Extensive-stage small-cell lung cancer (SCLC) patients who progress after platinum-based chemotherapy are traditionally categorized as platinum sensitive (progression ≥ 90 days from last platinum dose) or refractory (progression < 90 days), a practice arising from seminal observations of worse survival in refractory patients. Subsequent trials accounted for platinum sensitivity, resulting in higher sample sizes and increased resource use.

Methods: To assess whether platinum-sensitivity status remains associated with outcomes, patient-level data from recent Southwest Oncology Group trials in second- and/or third-line extensive-stage SCLC were pooled. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) accounting for platinum sensitivity were calculated using unadjusted and adjusted Cox Proportional Hazard models. Recursive partitioning was performed to define prognostic risk groups.

Results: Of 329 patients, 151 were platinum sensitive and 178 refractory. HRs from unadjusted Cox PFS and OS models for refractory versus sensitive disease were 1.0 (95% confidence interval, 0.81-1.25; p = 0.98) and 1.24 (0.99-1.57; p = 0.06), respectively. Adjusted Cox models showed that only elevated serum lactate dehydrogenase (HR, 2.04; p < 0.001), males (HR, 1.36; p = 0.04), performance status of 1 (HR, 1.25; p = 0.02), and weight loss greater than or equal to 5% (1.53, p = 0.01) were independently associated with OS. Platinum-sensitivity status was not associated with PFS (HR, 1.11; p = 0.49) or OS (HR, 1.25; p = 0.14), except in a model that excluded 36 patients who received more than one prior chemotherapy regimen (HR, 1.34; p = 0.049). Prognostic groups with differential OS outcomes (high, intermediate, and poor risk) were identified.

Conclusions: Platinum-sensitivity status may no longer be strongly associated with PFS or OS in at least one multivariate model. Validation of prognostic risk groups identified here is warranted. These data have critical implications in the design of future SCLC trials.

Trial registration: ClinicalTrials.gov NCT00068289 NCT00182689 NCT00828139.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan Meier Curves for Crude Progression-Free and Overall Survival, Stratified by Platinum Sensitivity Status (Unadjusted for Clinical Variables)
Figure 2
Figure 2
Recursive Partitioning Analysis of Platinum-Treated Small Cell Lung Cancer
Figure 3
Figure 3
See this image and copyright information in PMC

Comment in

References

    1. Schneider BJ. Management of recurrent small cell lung cancer. Journal of the National Comprehensive Cancer Network: JNCCN. 2008;6:323–31. - PubMed
    1. Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1988;6:1264–70. - PubMed
    1. Jotte RM, Conkling P, Reynolds C, et al. Second-line amrubicin (AMR) vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum based chemotherapy: updated results of a randomized phase 2 trial. Journal of Thoracic Oncology. 2009;4:S399-S.
    1. Morgensztern D, Perry MC, Govindan R. A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer. Acta oncologica. 2008;47:152–3. - PubMed
    1. Lara PN, Jr, Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327) Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2006;1:996–1001. - PubMed

Publication types

MeSH terms

Associated data